ABVX entered June with what should have been its finest hour. The Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis met its primary endpoint. Instead, shares closed at €63.10 on June 2 — down 43.6% on the day and 42.5% on the week — as safety data showing cancer cases in the treatment arm overwhelmed the efficacy headline.
The market reaction was swift and punishing. A drug that hits its primary endpoint in Phase 3 should be a catalyst for re-rating; here it triggered one of the sharpest single-day collapses the stock has seen. The tension at the heart of this week's note is exactly that contradiction: best-in-class efficacy data, a safety shadow that investors decided was too large to ignore.
The shift in short positioning tells the same story from another angle. Short Interest as a percentage of the free float jumped from 3.3% on June 1 to 4.6% by June 2 — a single-session addition of roughly one million shares. That follows a multi-week build: SI was near 2.3% in late May and has doubled in a month. The borrow market has tightened sharply in tandem. Availability collapsed from over 1,300% just a week ago to 20.6% on June 2, meaning only one share remains available to borrow for every five already lent out. Cost to borrow climbed to 2.78%, up 33% on the week. The borrow market has moved from entirely relaxed to genuinely tight in 48 hours. Short sellers are not finished repositioning.
The ORTEX short score underscores the momentum of that shift. It reached 68.2 on June 2, up from 47 just a week prior — a 21-point move in five sessions that places the score near its highest recent levels. The factor profile is mixed: EPS momentum over 90 days ranks in the 69th percentile, but the 30-day reading is in the 25th, reflecting how quickly the consensus landscape changed following the data release. Analyst activity has been immediate. Truist Securities maintained its Buy rating but cut its price target to $135 — a noteworthy adjustment that acknowledges the safety uncertainty without abandoning conviction. BTIG also reaffirmed its Buy on June 3. The analyst data on file is stale for formal consensus numbers, so only the directional signals from these recent reiterations are worth treating as current. Multiple law firm investigations into ABIVAX's officers and directors were announced within 24 hours of the data release — a standard post-crash response in US-listed biotechs, but one that adds headline noise.
The institutional register provides context on who was holding into the event. UBS Asset Management and Darwin Global Management each held close to 10% of shares at March 31. JPMorgan reported trimming its position by roughly 452,000 shares through mid-May, before the data. Goldman Sachs added modestly. The largest recent insider activity was a June 2026 award to CEO Marc De Garidel — share awards at zero price, carrying low significance ratings. The most material open-market insider transaction in the record was a board director sale at around €84-86 per share in November 2025, well above current levels. There is no signal of insider buying into the crash.
Correlated peers had a rough day too, though nothing approaching ABIVAX's scale. ZBIO fell 5.7% on the session and EQ dropped 9.4%, though EQ is still up more than 20% on the week, reflecting entirely separate drivers. The selloff in ABIVAX appears largely idiosyncratic rather than sector-wide.
The next formal event on the calendar is a September 21 earnings call. Between now and then, the story will turn on two things: how quickly regulators and the medical community interpret the cancer signal in the ABTECT data, and whether any additional clinical or safety communications from Abivax shift the risk assessment. The speed at which the borrow market has tightened suggests that short sellers expect that debate to remain unsettled for some time.
See the live data behind this article on ORTEX.
Open ABVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
